Chlorthalidone News and Research

RSS

Research sheds light on potential application of cyclodextrin derivatives in drug-supersaturated formulations

In the medicine market, most newly introduced drugs and drug candidates show poor water solubility, which prevents their absorption in the body.

15 May 2023

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Guideline-recommended diuretic linked to more side effects than similar antihypertensive drug

Chlorthalidone, the guideline-recommended diuretic for lowering blood pressure, causes more serious side effects than hydrochlorothiazide, a similarly effective diuretic, according to a new study led by researchers at Columbia University Irving Medical Center.

17 Feb 2020

Antihypertensive drug associated with lower risk of gout

Affecting more than 7 million adults in the United States, gout is characterized by a sudden onset of pain, swelling and stiffness in the joints and caused by the formation of urate crystal in small spaces between joints that builds up when high amounts of uric acid circulate in the blood.

27 Jan 2020

New statement provides detailed overview of how to diagnose, treat resistant hypertension

Resistant hypertension affects 12 percent to15 percent of patients treated for high blood pressure according to a new scientific statement from the American Heart Association.

14 Sep 2018

Pharmacotherapy reduces conduction system disease risk

Lisinopril therapy significantly reduces incident conduction system disease, indicates a post-hoc analysis of ALLHAT data.

28 Jun 2016

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

Chlorthalidone may reduce risk of death in patients with systolic hypertension

Patients with systolic hypertension who were treated with the diuretic chlorthalidone for 4.5 years as part of a clinical trial had a significantly lower rate of death and a gain in life expectancy free from cardiovascular death about 20 years later compared to patients who received placebo, according to a study in the December 21 issue of JAMA.

21 Dec 2011

Antihypertensive drug therapy associated with longer life expectancy

More than 68 percent of Americans 65 and older - 80 percent age 75 and over - have hypertension (high blood pressure), according to a 2010 report by the Centers for Disease Control. Left untreated, this chronic condition can lead to stroke, heart attack, heart failure or premature death. Researchers at UMDNJ-Robert Wood Johnson Medical School have shown in a follow-up to the landmark clinical trial, Systolic Hypertension in the Elderly Program (SHEP), that the use of antihypertensive drug therapy is associated with longer life expectancy.

21 Dec 2011

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.

21 Dec 2011

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda Global Research & Development Center, Inc. U.S., today announced results from three phase 3 studies of the investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone.

24 May 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that EDARBI, an angiotensin II receptor blocker approved for the treatment of hypertension, or high blood pressure, is now available by prescription for adults in U.S. pharmacies.

15 Apr 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

Study examines comparative value of different blood pressure lowering medications

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.

13 Aug 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Diuretic drug works best at reducing risk of heart failure in hypertension

New research supports the findings of a landmark drug comparison study published in 2002 in which a diuretic drug or "water pill" outperformed other medications for high blood pressure. A scientific team including investigators from The University of Texas Health Science Center at Houston reports the findings in the May 11 issue of the Archives of Internal Medicine.

13 May 2009

Potassium loss from blood pressure drugs increases diabetes risk by 50%

According to researchers in the U.S. the loss of potassium experienced from taking blood pressure drugs may explain higher risk of adult diabetes.

25 Nov 2008

Potassium loss caused by diuretics may explain higher risk of adult diabetes

Johns Hopkins researchers have discovered that a drop in blood potassium levels caused by diuretics commonly prescribed for high blood pressure could be the reason why people on those drugs are at risk for developing type 2 diabetes.

24 Nov 2008

Diuretic reduces risk for type of heart failure that affects women more often than

New research by The University of Texas School of Public Health shows that a medication for high blood pressure called a diuretic or water pill is particularly effective at reducing the risk for a type of heart failure that affects women more often than men.

11 Nov 2008

Chlorthalidone News and Research

Research sheds light on potential application of cyclodextrin derivatives in drug-supersaturated formulations

Results of high-impact clinical trials could affect kidney-related medical care

Guideline-recommended diuretic linked to more side effects than similar antihypertensive drug

Antihypertensive drug associated with lower risk of gout

New statement provides detailed overview of how to diagnose, treat resistant hypertension

Pharmacotherapy reduces conduction system disease risk

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Chlorthalidone may reduce risk of death in patients with systolic hypertension

Antihypertensive drug therapy associated with longer life expectancy

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Azilsartan medoxomil-CLD phase 3 study results in systolic blood pressure presented at ASH 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Study examines comparative value of different blood pressure lowering medications

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Diuretic drug works best at reducing risk of heart failure in hypertension

Potassium loss from blood pressure drugs increases diabetes risk by 50%

Potassium loss caused by diuretics may explain higher risk of adult diabetes

Diuretic reduces risk for type of heart failure that affects women more often than

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News